— Matinas BioPharma (NYSE: MTNB) reported loss of $0.04 per share in the fourth quarter of 2019, vs $0.03 per share loss expected.
— Initiated ENHANCE-IT study of MAT9001 against Vascepa. Topline data expected Q4 2020.
— Cash, cash equivalents and marketable securities at December 31, 2019 were approx. $27.8 million, compared to $12.4 million a year ago.
— MTNB shares ended down 2.75% in its last trading session on Friday.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Earnings Preview: FedEx looks set to report mixed results for Q4 2025
FedEx Corp. (NYSE: FDX) is preparing to report fourth-quarter earnings on Tuesday, June 24, at 4:00 pm ET. Recently, the management lowered its full-year earnings and revenue guidance for the
How Ulta Beauty’s (ULTA) new strategy is fueling growth
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) were up over 1% on Monday. The stock has gained 31% over the past three months. The beauty retailer started fiscal year 2025
Earnings Preview: What to look for when Kroger (KR) reports Q1 2025 results
The Kroger Co. (NYSE: KR) is expected to report its first-quarter financial results next week. Customer engagement remained stable last year, driven by high-quality products and tailored promotional offers. Recently,
